Pneumococcal conjugate 7-valent vaccine – consisting of 2-4 µg of capsular polysaccharide antigens from the following serotypes - 4, 6B, 9V, 14, 18C, 19F, 20, and 23F conjugated to non-toxic diphtheria toxin (CRM197).

Market Analysis and Insights: Global and USA 7-Valent Pneumococcal Vaccine Market
This report focuses on global and USA 7-Valent Pneumococcal Vaccine market.
In 2020, the global 7-Valent Pneumococcal Vaccine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In USA the 7-Valent Pneumococcal Vaccine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global 7-Valent Pneumococcal Vaccine Scope and Market Size
7-Valent Pneumococcal Vaccine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global 7-Valent Pneumococcal Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For USA market, this report focuses on the 7-Valent Pneumococcal Vaccine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in USA.

Segment by Type
Single Dose Vial
Pre-filled Syringe

Segment by Application
Hospital
Clinic

By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Merck